Skip to main navigation

Back to SpringWorksTx.com
Investors & Media
Contact Us
Linkedin
Twitter

Overview
News & Events
- Press Releases
- Events & Presentations
Corporate Governance
Financial Information
- SEC Filings
- Annual Reports
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Investor Resources
Investors + Media
Medical Professionals
Contact Us
Linkedin
Twitter

Press Releases

Items Per Page

Year

24 May 2023

SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

PDF Version

11 May 2023

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

PDF Version

03 May 2023

SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

PDF Version

02 May 2023

SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference

PDF Version

17 Apr 2023

SpringWorks and BeiGene Present Clinical Data on Lifirafenib in combination with Mirdametinib in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

PDF Version

17 Apr 2023

MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

PDF Version

08 Mar 2023

SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors

PDF Version

01 Mar 2023

SpringWorks Therapeutics to Participate in the TD Cowen 43rd Annual Health Care Conference

PDF Version

28 Feb 2023

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

PDF Version

27 Feb 2023

SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors

PDF Version

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 41 - 50 of 157

Springworks - Toolkits

Print Page
Email Alerts
RSS Feeds
Investor Contacts

Request E-mail Alerts

Social Links

Footer 1

Who We Are
Focus Areas

Footer 2

Pipeline
Careers
- View Opportunities

Footer 3

Patients
Contact

Footer 4

Investors & Media

© 2024 SpringWorks Therapeutics. All rights reserved.

Copyright Links

Privacy Policy
Terms of Use
Cookie Policy